JAK2 and myeloproliferative neoplasm: After a first study which evaluated the efficacy of ruxolitinib in preclinical models of JAK2 V617F positive MPN [28], a phase I-II [30] and two phase III clinical trials (COMFORT I and II) were carried out with positive results [31, 32].